Vaxart, Inc.·4

Mar 26, 4:52 PM ET

Cummings James F. 4

Research Summary

AI-generated summary

Updated

Vaxart CMO James Cummings Withholds 30,551 Shares for Taxes

What Happened
James F. Cummings, Chief Medical Officer of Vaxart, reported that 30,551 shares were disposed on March 24, 2026 as a tax-withholding event tied to the net settlement of vested restricted stock units (RSUs). The shares were withheld at $0.69 per share, for a total of $21,202. This was an issuer withholding to satisfy income tax obligations (transaction code F), not an open-market sale for cash.

Key Details

  • Transaction date and price: 2026-03-24 — 30,551 shares withheld @ $0.69 per share (total $21,202).
  • Transaction type: F — shares withheld to satisfy tax withholding on vested RSUs (net settlement).
  • Shares owned after transaction: Not specified in the Form 4 filing.
  • Footnotes: F1 confirms shares were withheld by the issuer to satisfy income tax withholding for RSUs vested on March 24, 2026. F2 notes 75,618 shares were acquired under Vaxart’s 2022 Employee Stock Purchase Plan (ESPP) and are included in the filing’s reported amounts.
  • Timeliness: Form 4 filed on 2026-03-26 for the 2026-03-24 transaction — filed within the typical 2-business-day reporting window.

Context
This is a routine tax-withholding transaction that reduces the number of shares delivered on RSU vesting; it does not necessarily indicate the insider’s view of the stock. Purchases or open-market sales tend to be more informative about insider sentiment than withholding events.